Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Regeneron Pharmaceuticals : Announces Upcoming Investor Conference Presentation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/18/2018 | 03:31pm CEST

TARRYTOWN, N.Y., May 18, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Goldman Sachs 39th Annual Global Healthcare Conference at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) on Tuesday, June 12, 2018.

The session may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.  A replay of the webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:  


Investor Relations           

Corporate Communications

Manisha Narasimhan, Ph.D.                   

Hala Mirza

914.847.5126    

914.847.3422             

manisha.narasimhan@regeneron.com

hala.mirza@regeneron.com

 

Cision View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentation-300650631.html

SOURCE Regeneron Pharmaceuticals, Inc.


© PRNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
08/14REGENERON PHARMACEUTICALS : FDA issues CRL for 12-week Eylea regimen
AQ
08/13REGENERON PHARMACEUTICALS : Provides Regulatory Update on EYLEA® (aflibercept) I..
PR
08/10REGENERON PHARMACEUTICALS : and bluebird bio Announce Collaboration to Discover,..
AQ
08/09REGENERON PHARMACEUTICALS : New Ebola Virus Data Have Been Reported by Investiga..
AQ
08/09REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Rotatable Su..
AQ
08/09REGENERON PHARMACEUTICALS : Announces the 2018 Winners of the Prize for Creative..
AQ
08/08NASDAQ 100 MOVERS : Myl, qrtea
AQ
08/07REGENERON PHARMACEUTICALS : Pharma and Bluebird bio announce immune cell collabo..
AQ
08/06REGENERON PHARMACEUTICALS : bluebird bio and Regeneron Announce Collaboration to..
BU
08/03REGENERON PHARMACEUTICALS : Announces the 2018 Winners of the Prize for Creative..
PR
More news
News from SeekingAlpha
08/15REGENERON : A Buy On Dupixent And Pipeline 
08/14YOUR DAILY PHARMA SCOOP : Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA.. 
08/13Regeneron's Pain Is Novartis' Gain 
08/13ZOETIS : Stock To Outperform On Long-Term Focus On Growth 
08/13FDA rejects Regeneron's application for 12-week dosing of Eylea for wet AMD